Acutaas Chemicals Peer Comparison

NSE: ACUTAAS | BSE: 543349

₹3,196.50

₹-82.90 (-2.53%)

As on 01-Oct-2026IST

Market cap

₹26,160 Cr

Revenue (TTM)

₹1,462 Cr

P/E Ratio

67.7

P/B Ratio

15.2

Div. Yield

0.1 %

Edit

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Market cap (₹ Cr)	26,160	33,904	27,051	26,327	22,390
Revenue (₹ Cr)	1,462	3,564	1,936	9,205	5,632
Net Profit (₹ Cr)	387.35	414.00	288.22	-371.81	662.35
Net Margin (%)	26.01	11.23	14.79	-3.93	11.75
RoE (%)	25.18	8.38	29.77	-3.85	14.34
Price to Earnings	67.73	82.89	93.86	--	33.80
Price-To-Book	15.16	6.73	20.15	3.29	4.57

Income Statement (₹ Cr)

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Operating Revenue	1,461.80	3,564.00	1,935.80	9,205.28	5,632.31
Total Income	1,489.25	3,686.00	1,948.58	9,449.59	5,638.56
Total Expenditure	919.25	2,792.00	1,485.56	8,195.15	4,354.97
EBITDA	542.56	772.00	450.24	1,010.13	1,277.34
Depreciation	37.68	226.00	50.83	857.51	306.94
EBIT	504.88	546.00	399.41	152.62	970.39
Interest	3.77	217.00	40.84	342.73	111.70
Other Income	27.45	122.00	12.78	244.31	6.25
Exceptional Items	0.00	12.00	0.00	-216.88	15.92
Profit before Tax	528.56	463.00	371.35	-162.68	880.86
Provision for Tax	141.21	49.00	83.14	209.13	218.51
Profit after Tax	387.35	414.00	288.22	-371.81	662.35

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Shareholder's Funds	1,653.56	4,940.00	1,288.82	8,162.62	5,085.00
Minority Interest	-1.13	-5.00	0.00	0.00	0.00
Non-Current Liabilities	42.40	1,712.00	202.03	5,044.14	542.92
Current Liabilities	230.82	1,622.00	835.87	4,758.28	2,092.03
Total Liabilities	1,983.96	8,578.00	2,326.71	17,723.32	7,682.91

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Non-Current Assets	1,026.85	5,343.00	519.60	10,211.52	3,533.26
Current Assets	881.27	2,606.00	1,681.81	7,191.66	3,767.65
Total Assets	1,983.96	8,578.00	2,326.71	17,723.32	7,682.91
Total Debt*	26.49	2,125.00	259.37	5,495.48	1,338.13
Net Current Assets	650.46	984.00	845.94	2,433.38	1,675.62
Contingent Liabilities	17.25	768.26	19.09	95.72	0.93

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Cash From Operating Activities	292.17	390.00	205.05	1,652.60	793.25
Cash Flow from Investing Activities	-265.94	-241.00	-409.72	-826.03	-773.21
Cash from Financing Activities	4.10	-54.00	283.07	-38.98	379.29
Net Cash Inflow / Outflow	30.33	95.00	78.39	787.59	399.33

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
ROCE (%)	32.42	6.79	29.22	1.24	15.74
ROE (%)	25.18	8.38	29.77	-3.85	14.34
ROA (%)	21.93	4.94	24.77	-2.21	9.48
EBIT Margin (%)	34.54	15.32	20.63	1.66	17.23
Net Margin (%)	26.01	11.23	14.79	-3.93	11.75
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Revenue Growth (%)	40.90	18.37	46.65	0.78	24.83
EBIT Growth (%)	124.50	252.26	62.13	-70.53	40.39
Net Profit Growth (%)	104.15	377.85	89.49	-1,383.43	38.13
EPS Growth (%)	42.32	1,001.33	78.60	-484.84	34.88
Book Value Growth (%)	26.03	13.47	144.31	0.33	27.49

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Price / Earnings	67.73	85.08	92.42	-84.14	31.00
Price / Book Value	15.16	6.73	20.15	3.29	4.57
Dividend Yield (%)	0.08	0.00	0.09	0.00	0.21
EV/EBITDA	47.85	45.81	59.89	30.16	17.83
Market Cap (₹ Cr)	20,944.75	19,071.62	12,753.19	18,108.89	15,391.88

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Debt to Equity	0.02	0.31	0.11	0.53	0.06
Short term debt to equity ratio	0.02	0.09	0.05	0.09	0.20
Current Ratio	3.82	1.61	2.01	1.51	1.80
Quick Ratio	2.82	1.06	1.14	0.87	1.00
Interest Coverage	141.16	3.13	10.09	0.53	8.89

	Acutaas Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Granules India
Debtors to sales (%)	24.80	16.50	26.28	23.44	16.15
Asset Turnover	0.83	0.43	1.66	0.55	0.81
Receivable days	88.98	58.75	40.13	78.20	33.72
Inventory Days	56.04	75.82	60.29	93.30	54.92
Payable days	99.95	186.21	232.47	226.14	136.11
Cash Conversion Cycle	45.07	-51.64	-132.04	-54.64	-47.47

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.